Shockwave Therapy Surpasses Standard of Care in First-Line Diabetic Wound and Pressure Ulcer Treatment
Pulsed Acoustic Cellular Expression (PACE®) is a proprietary form of extracorporeal shockwave technology (ESWT) that utilizes high-energy, nonthermal acoustic pressure waves generated via an electric discharge inside a fluid, which is known as electrohydraulic method. Specially modulated shockwaves are delivered directly into the wound bed and periwound that penetrate deep inside the tissue to promote wound healing and wound closure.
PACE therapy is more likely to achieve wound closure than standard first-line wound care treatments. Its unique mechanism of action (MOA) helps explain why PACE-treated wounds heal better and faster.
This proven solution helps expedite the healing process at the cellular level, resulting in less time and resources spent on costly treatments that are not as effective. SANUWAVE’s dermaPACE System* offers a better, simpler, and cost-effective alternative to the traditional standard of care or other advanced wound therapies, for improved patient outcomes and enhanced quality of life.
How PACE Technology Works
Wound Healing Benefits of PACE Therapy
*The dermaPACE System is the first shockwave system to be FDA-cleared for the treatment of diabetic foot ulcers (DFU) in the United States. It is CE-marked in Europe for application in acute and chronic defects of the skin and subcutaneous tissues. These include:
- Post-operative wound healing defects
- Post-traumatic wounds
- Deep, partial-thickness burns
- Decubitus ulcers (pressure ulcers)
- Diabetic ulcers
- Arterial ulcers
- Venous ulcers
- Li et al. Improvement of Blood Flow, Expression of Nitric Oxide, and Vascular Endothelial Growth Factor by Low-Energy Shockwave Therapy in Random-Pattern Skin Flap Model. Annals of Plastic Surgery. 2008 Dec;61(6):646-53.
- Krokowicz et al. Microcirculatory response to shockwave therapy in acute model – preliminary report. Presented during the International Society for Musculoskeletal Shockwave Therapy, Toronto, Canada, June 2007.
- Sanctis et al. Effects of Shock Waves on the Microcirculation in Critical Limb Ischemia (CLI) (8-Week Study). Angiology. 2000 Aug;51(8:2): S69-78.
- Wanner et al. Low-energy shock waves enhance the susceptibility of staphylococcal biofilms to antimicrobial agents in vitro. J Bone Joint Surg Br. 2011 Jun;93(6):824-7.
- Siemionow et al. Pulsed Acoustic Cellular Therapy Supports Pro-angiogenic Factors Expression in Ischemic Muscles. Poster presentation at the Diabetic Foot Conference 2008.
- Davis et al. Extracorporeal Shock Wave Therapy Suppresses the Early Pro-Inflammatory Immune Response to a Severe Cutaneous Burn Injury. International Wound Journal. Vol 6, No 1. 2008.
- Stojadinovic et al. Angiogenic response to Extracorporeal Shock Wave Treatment in Murine Skin Isografts. Angiogenesis. 2009 2008;11(4):369-80
- Wang et al. Molecular Changes in Diabetic Foot Ulcers. Diabetes Research and Clinical Practice. 2011.
- Wang CJ et al. Biological Mechanism of Musculoskeletal Shockwaves. International Society for Musculoskeletal Shockwave Therapy Newsletter, Volume 1, Issue 1, 2004.
- Meier R, Brunner A, Deibl M, Oehlbauer M, Piza-Katzer H, Kamelger FS, Shock wave therapy reduces necrotic flap zones and induces VEGF expression in animal epigastric skin flap model. J Reconstr Microsurg. 2007 May; 23(4):231-6.
- Meier R, Heumer GM, Oehlbauer M, Wanner S, Piza-Katzer H, Kamelger FS, Comparison of the effectiveness of gene therapy with vascular endothelial growth factor or shockwave therapy to reduce ischemic necrosis in an epigastric skin flap model in rats. J Plast Reconstr Aesthet Surg. 2007;60(3):266-71.
- Kamelger et al. Comparison of the Effectiveness of Gene Therapy with Vascular Endothelial Growth Factor or Shock Wave Therapy to Reduce Ischaemic Necrosis in an Epigastric Skin Flap Model in Rats. 2007; 60:266-271.
- Saggini et al. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. Ultrasound Med Biol. 2008 Aug;34(8):1261-71.
- Phase III Pivotal Trial Results of dermaPACE for the Treatment of Diabetic Foot Ulcers. Data on file with SANUWAVE Health, Inc.